MEDI9197 is an imidazoquinoline analogue toll-like receptor (TLR) agonist that can be used for cancer immunotherapy based on its efficacy toward a variety of tumors.

MD2-TLR4-IN-1 is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex.

CU-CPT9a is a selective Toll-like receptor 8 (TLR8) inhibitor with IC50 of 0.5 nM. It can also suppress TNF-α levels.

SM-324405 is a selective TLR7 agonist with antedrug characteristics.

TLR7 agonist T7 is a novel Toll-like receptor 7 (TLR7) agonist, eliciting the nonspecific antitumor responses and strengthening the specific humoral and cellular immune responses.

Afimetoran is an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor.

IAXO-102 is a novel small molecule TLR4 antagonist.

Selective toll-like receptor 1/2 (TLR1/2) inhibitor (IC50 = 0.58 μM). Exhibits no activity at TLR2/TLR6, TLR3, TLR4 and TLR7 or a panel of 10 representative kinases. Inhibits the release of proinflammatory cytokines TNF-α and IL-1β.

C34 is a TLR4 inhibitor.

CU-CPT17e is a multi-Toll-like receptor (TLR3/8/9) agonist with proinflammatory and anticancer activities.

GS-9620 is a selective agonist of Toll-like receptor 7 (TLR-7) in chimpanzees and has anti-HBV infection activity.

PF-4878691 is a potent and selective Toll-like receptor 7 (TLR7) agonist.

Loxoribine, a guanosine analog, is selective agonist of Toll-like receptor 7 with anti-viral and anti-tumor activities.

Gardiquimod trifluoroacetate is a specific TLR7 agonist.

Selgantolimod is a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.